Literature DB >> 55556

Letter: Clofibrate-induced myopathy syndrome.

K W Rumpf, R Albers, F Scheler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 55556     DOI: 10.1016/s0140-6736(76)91369-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Modulation of the gating of CIC-1 by S-(-) 2-(4-chlorophenoxy) propionic acid.

Authors:  E C Aromataris; D S Astill; G Y Rychkov; S H Bryant; A H Bretag; M L Roberts
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 2.  Bezafibrate induced rhabdomyolysis.

Authors:  E Kanterewicz; R Sanmartí; J Riba; I Trias; J Autonell; J Brugués
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

3.  Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.

Authors:  A Bardosi; P Scheidt; H H Goebel
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

4.  [Fat and renal failure--therapeutic aspects].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-08

Review 5.  Adverse effects of drugs on muscle.

Authors:  F L Mastaglia
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

6.  [Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function].

Authors:  K W Rumpf; M Barth; M Blech; H Kaiser; I Koop; R Arnold; F Scheler
Journal:  Klin Wochenschr       Date:  1984-04-16

7.  Myotonia induced with clofibrate in rats.

Authors:  H Kwieciński
Journal:  J Neurol       Date:  1978-10-25       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.